Notably, we are well on our way through the drug approval pathway process.

We have refined our technology and our Generation VI Micro-Needle, our final and perfected device, was finalized in 2018. It has passed all testing with 100 per cent reliability. We now must confirm efficacy and safety in order to receive regulatory approvals and be available for potential drug company licences. Our next step is to complete veterinary clinical trials, which shall be conducted in 2022 at the University of Guelph, Ontario. 

We are now raising a fourth round of capital to perform human clinical trials and secure licenses with pharmaceutical companies who will then manufacture and sell our device in the human medical market.  By investing, you will receive shares and become a co-owner of PKA SoftTouch, and have the potential to profit from the sale of each and every device. 


The following article was written by two of PKA SoftTouch’s founders: Dr. Pankaj Modi and Maneesh Khanna – together with Marko Mihic.

The article provides information on early testing and results of the Micro-Needle.



A key component for financial success and stability is the protection of our technology. Patentability also plays a vital role in a medical device company’s shareholder value.

We have protected our intellectual property in 23 countries: Canada, United States, India, Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Poland, Spain, Sweden, Switzerland, United Kingdom, Japan, New Zealand, South Africa, Brazil and Australia. Patents are still pending in Argentina.

Applied for US PCT in 2019, to update recent improvements in our device technology. Presently, PKA is perfecting in some countries that we are protected in with initial patents. More importantly this will extend the patent protection by 20 years.